ProjectStudie MK3475-716
Basic data
Title:
Studie MK3475-716
Duration:
02/05/2019 to 29/10/2029
Abstract / short description:
Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk
Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)
Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE 716)
Involved staff
Managers
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
München, Bayern, Germany